Leukemia Research
Volume 28, Issue 12 , Pages 1267-1271 , December 2004

Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2’-deoxycytidine (decitabine)

  • Michael Lübbert

      Affiliations

    • Department of Hematology/Oncology, University of Freiburg, Medical Center, Hugstetter Str. 55, D 79106 Freiburg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 761 270 3279; fax: 49 761 270 3697.
    • ,
  • Michael Daskalakis

      Affiliations

    • Department of Hematology/Oncology, University of Freiburg, Medical Center, Hugstetter Str. 55, D 79106 Freiburg, Germany
    • ,
  • Regina Kunzmann

      Affiliations

    • Department of Hematology/Oncology, University of Freiburg, Medical Center, Hugstetter Str. 55, D 79106 Freiburg, Germany
    • ,
  • Monika Engelhardt

      Affiliations

    • Department of Hematology/Oncology, University of Freiburg, Medical Center, Hugstetter Str. 55, D 79106 Freiburg, Germany
    • ,
  • Yalin Guo

      Affiliations

    • Department of Hematology/Oncology, University of Freiburg, Medical Center, Hugstetter Str. 55, D 79106 Freiburg, Germany
    • ,
  • Pierre Wijermans

      Affiliations

    • Department of Medicine/Hematology, Leyenburg Hospital, Leyweg 275, NL 2545, CH, The Hague, The Netherlands

Received 11 February 2004 ,Accepted 7 April 2004.

References 

  1. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature. 1977;267:364–366
  2. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 1982;257:2041–2048
  3. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984;64:922–929
  4. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group. J. Clin. Oncol. 2002;20:2429–2440
  5. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al.  Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome, a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000;18:956–962
  6. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al.  Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br. J. Haematol. 2001;114:349–357
  7. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood. 1993;81:1580–1585
  8. Vyas RC, Frankel SR, Agbor P, Miller WH, Warrell RP, Hittelman WN. Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromosome condensation/ fluorescence in situ hybridization analysis. Blood. 1996;87:218–226
  9. Lübbert M, Miller CW, Koeffler HP. Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. Blood. 1991;78:345–356
  10. Daskalakis M, Nguyen TT, Guldberg P, Köhler G, Wijermans P, Jones PA, et al.  Demethylation of a hypermethylated 15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine treatment. Blood. 2002;100:2957–2964
  11. Sakashita K, Kenichi K, Kinoshita T, Shiohara M, Kamijo T, Taniguchi S, et al.  Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. J. Clin. Invest. 2001;108:1195–1204
  12. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajahy, Hoffman R., Modification of hematopoietic stem cell fate by 5-aza-2′deocycytidine and trichostatin A, Blood 2004;103:4102–10.
  13. Sigalotti L, Altomonte M, Colizzi F, Degan M, Zagonel V, Pinto A, et al.  5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood. 2003;101:4644–4645
  14. van den Bosch J, Lübbert M, Verhoef G, Wijermans PW. Effects of 5-Aza-2′deoxycytidine (Decitabine) on the platelet count in patients with high-risk myelodysplastic syndromes. Leuk Res. 2004;28:785–790

PII: S0145-2126(04)00130-4

doi: 10.1016/j.leukres.2004.04.002

Leukemia Research
Volume 28, Issue 12 , Pages 1267-1271 , December 2004

Article Tools

* Image Usage & Resolution